scholarly journals Peptide-Mediated Liposomal Drug Delivery System Targeting Tumor Blood Vessels in Anticancer Therapy

2010 ◽  
Vol 2010 ◽  
pp. 1-8 ◽  
Author(s):  
Han-Chung Wu ◽  
De-Kuan Chang
Keyword(s):  
Drug Delivery ◽  
Endothelial Cells ◽  
Blood Vessels ◽  
Antiangiogenic Therapy ◽  
Anticancer Therapy ◽  
Liposomal Drug ◽  
Surface Receptors ◽  
Low Toxicity ◽  
Tumor Blood Vessels ◽  
Potential Methods

Solid tumors are known to recruit new blood vessels to support their growth. Therefore, unique molecules expressed on tumor endothelial cells can function as targets for the antiangiogenic therapy of cancer. Current efforts are focusing on developing therapeutic agents capable of specifically targeting cancer cells and tumor-associated microenvironments including tumor blood vessels. These therapies hold the promise of high efficacy and low toxicity. One recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics is to encapsulate anticancer drugs into targeting liposomes that bind to the cell surface receptors expressed on tumor-associated endothelial cells. These anti-angiogenic drug delivery systems could be used to target both tumor blood vessels as well as the tumor cells, themselves. This article reviews the mechanisms and advantages of various present and potential methods using peptide-conjugated liposomes to specifically destroy tumor blood vessels in anticancer therapy.

scholarly journals A New Antitumor Direction: Tumor-Specific Endothelial Cells

2021 ◽  
Vol 11 ◽  
Author(s):  
Jing Liang ◽  
Shouqi Wang ◽  
Guowei Zhang ◽  
Baoyu He ◽  
Qingli Bie ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Endothelial Cells ◽  
Side Effects ◽  
Tumor Microenvironment ◽  
Blood Vessels ◽  
Antiangiogenic Therapy ◽  
Clinical Effects ◽  
Antiangiogenic Drugs ◽  
Tumor Blood Vessels ◽  
New Treatment

Targeting tumor blood vessels is an important strategy for tumor therapies. At present, antiangiogenic drugs are known to have significant clinical effects, but severe drug resistance and side effects also occur. Therefore, new specific targets for tumor and new treatment methods must be developed. Tumor-specific endothelial cells (TECs) are the main targets of antiangiogenic therapy. This review summarizes the differences between TECs and normal endothelial cells, assesses the heterogeneity of TECs, compares tumorigenesis and development between TECs and normal endothelial cells, and explains the interaction between TECs and the tumor microenvironment. A full and in-depth understanding of TECs may provide new insights for specific antitumor angiogenesis therapies.

scholarly journals Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Sijumon Kunjachan ◽  
Shady Kotb ◽  
Robert Pola ◽  
Michal Pechar ◽  
Rajiv Kumar ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Blood Vessels ◽  
Fold Increase ◽  
Effective Drug ◽  
Human Pancreatic Cancer ◽  
Standard Drug ◽  
Fluorescence Studies ◽  
Nanodrug Delivery ◽  
Functional Changes ◽  
Tumor Blood Vessels

Abstract Effective drug delivery is restricted by pathophysiological barriers in solid tumors. In human pancreatic adenocarcinoma, poorly-permeable blood vessels limit the intratumoral permeation and penetration of chemo or nanotherapeutic drugs. New and clinically viable strategies are urgently sought to breach the neoplastic barriers that prevent effective drug delivery. Here, we present an original idea to boost drug delivery by selectively knocking down the tumor vascular barrier in a human pancreatic cancer model. Clinical radiation activates the tumor endothelial-targeted gold nanoparticles to induce a physical vascular damage due to the high photoelectric interactions. Active modulation of these tumor neovessels lead to distinct changes in tumor vascular permeability. Noninvasive MRI and fluorescence studies, using a short-circulating nanocarrier with MR-sensitive gadolinium and a long-circulating nanocarrier with fluorescence-sensitive nearinfrared dye, demonstrate more than two-fold increase in nanodrug delivery, post tumor vascular modulation. Functional changes in altered tumor blood vessels and its downstream parameters, particularly, changes in Ktrans (permeability), Kep (flux rate), and Ve (extracellular interstitial volume), reflect changes that relate to augmented drug delivery. The proposed dual-targeted therapy effectively invades the tumor vascular barrier and improve nanodrug delivery in a human pancreatic tumor model and it may also be applied to other nonresectable, intransigent tumors that barely respond to standard drug therapies.

Antiangiogenic Therapy Decreases Integrin Expression in Normalized Tumor Blood Vessels

2006 ◽  
Vol 66 (5) ◽  
pp. 2639-2649 ◽  
Author(s):  
Virginia J. Yao ◽  
Michael G. Ozawa ◽  
Amanda S. Varner ◽  
Ian M. Kasman ◽  
Yvan H. Chanthery ◽  
...  
Keyword(s):  
Blood Vessels ◽  
Antiangiogenic Therapy ◽  
Integrin Expression ◽  
Tumor Blood Vessels

Peptide-guided drug delivery to radiation-induced targets in tumor blood vessels

2003 ◽  
Vol 57 (2) ◽  
pp. S317-S318
Author(s):  
A Cmelak ◽  
B Chak ◽  
C Scarfone ◽  
W Martin ◽  
D Hallahan
Keyword(s):  
Drug Delivery ◽  
Blood Vessels ◽  
Radiation Induced ◽  
Tumor Blood Vessels

Analysis of multidrug resistant transporter expression in tumor blood vessels of urothelial carcinoma during chemotherapy.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e23004-e23004
Author(s):  
Hiroshi Kikuchi ◽  
Nako Maishi ◽  
Kosuke Akiyama ◽  
Masahiro Morimoto ◽  
Misa Yanagiya ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Endothelial Cells ◽  
Blood Vessels ◽  
Tumor Cells ◽  
Cancer Drug ◽  
Cancer Drug Resistance ◽  
Before And After ◽  
Mdr1 Mrna ◽  
Tumor Blood Vessels ◽  
Line Chemotherapy

e23004 Background: ABCB1, a multidrug transporter, is encoded by multidrug resistance (MDR) 1 gene and plays a major role in drug resistance. Recently, we have reported that not only tumor cells, tumor vascular endothelial cells (TECs) also confer cancer drug resistance. We isolated TECs and found that they have various abnormalities such as aneuploidy or stemness characteristics. TECs showed resistance to Paclitaxel (PTX) with ABCB1 up-regulation. Furthermore, their resistance to PTX was abrogated by ABCB1 inhibition of TECs in vivo. In clinical urology, gemcitabine / cisplatin (GC) is standard 1st line chemotherapy for metastatic urothelial carcinoma (mUC). PTX is often selected in 2nd line chemotherapy for GC resistant cases, however the therapeutic outcomes are limited. We hypothesized that ABCB1 inhibitor/PTX combination would be more effective strategy for mUC, if TEC ABCB1 expression is upregulated. In this study, we investigated ABCB1 expression in tumor blood vessels of UC during 1st line chemotherapy. Methods: Paraffin-embedded samples were corrected from 50 patients who were performed tumor resection before and after 1st line chemotherapy. ABCB1 expressions were analyzed by immunohistochemical staining and the ratio of ABCB1 positive (+) vessels in total vessels were quantified. In vitro assays were performed to address how endothelial cells (ECs) are affected by change of tumor microenvironment during chemotherapy. Results: The ABCB1 (+) vessels were 0.00 – 16.80% (Median 0.00%) and 0.00-58.94% (Median 4.49%), before and after chemotherapy, respectively. In 32 of 50 cases (64%), the ratio of ABCB1 (+) vessels increased after 1st line chemotherapy. Additionally, gemcitabine induced MDR1 mRNA expression in ECs via NF-kB activation. Furthermore, gemcitabine and cisplatin induced IL-8 secretion from tumor cells, and MDR1 mRNA expression level was elevated in ECs. Conclusions: It was suggested that conventional chemotherapy may cause inflammatory change in tumor tissues, which causes in ABC transporter induction in tumor blood vessels. It was suggested that inhibition of ABC transporter in TECs is one of important new strategy to overcome cancer drug resistance.

Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay

2004 ◽  
Vol 99 (3) ◽  
pp. 369-381 ◽  
Author(s):  
Ling Geng ◽  
Katherine Osusky ◽  
Sekhar Konjeti ◽  
Allie Fu ◽  
Dennis Hallahan
Keyword(s):  
Drug Delivery ◽  
Tumor Growth ◽  
Blood Vessels ◽  
Growth Delay ◽  
Tumor Growth Delay ◽  
Tumor Blood Vessels
Sign in / Sign up

Export Citation Format

Share Document